<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810262</url>
  </required_header>
  <id_info>
    <org_study_id>D50772</org_study_id>
    <nct_id>NCT02810262</nct_id>
  </id_info>
  <brief_title>Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS)</brief_title>
  <acronym>POUMOS</acronym>
  <official_title>Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mortality due to non small cell lung cancers is the first cause of cancer death in men around
      the world. Lung adenocarcinoma regularly induces bone metastases responsible for high
      morbidity and impaired life quality. Overall survival of these patients is poor. Thus the
      investigators aimed to identify if some bone and metabolic parameters were associated with
      overall survival.

      Patients and Methods POUMOS is a prospective cohort of patients suffering from adenocarcinoma
      lung cancers with a first bone metastasis (stage IV). All patients have a bone biopsy with
      molecular status characterization of the tumor for EGFR, KRAS, BRAF and ALK. Bone metastasis
      localizations are obtained by bone scintigraphy or FDG-PET/CT. Whole body composition is
      obtained by DEXA scan (Hologic®). The investigators assessed also fasting blood levels of
      bone and metabolic biomarkers.

      Survival analyses will be performed using a proportional hazard regression model.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>serum DKK1</measure>
    <time_frame>day 0</time_frame>
    <description>Biomarkers are assessed at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum HbA1C</measure>
    <time_frame>day 0</time_frame>
    <description>Biomarkers are assessed at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary CTX</measure>
    <time_frame>day 0</time_frame>
    <description>Biomarkers are assessed at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hip bone mass (g/cm²)</measure>
    <time_frame>day 0</time_frame>
    <description>Whole body densitometry is performed at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mutational profile of the bone metastases</measure>
    <time_frame>day 0</time_frame>
    <description>Molecular characterization of the bone metastases by PCR (EGFR, KRAS, BRAF) and FISH (ALK)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bone Metastases</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>First bone metastasis of adenocarcinoma lung cancer</arm_group_label>
    <description>Patients entering the group have a suspected first bone metastasis of adenocarcinoma lung cancer and should undergo bone biopsy to histologically prove the diagnosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bone metastases biopsy</intervention_name>
    <description>The vast majority of bone biopsy are performed under CT-scan. In some rare cases, the histology will be performed during surgery (either biopsy of the bone metastasis or surgical piece when treating a fracture).</description>
    <arm_group_label>First bone metastasis of adenocarcinoma lung cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine Serum and plasma Bone biopsy Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        POUMOS is a prospective cohort of patients suffering from adenocarcinoma lung cancers with
        a first bone metastasis (stage IV). All patients have a bone biopsy with molecular status
        characterization of the tumor
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults over 18 years

          -  both gender

          -  covered by the French National Insurance

          -  first bone metastases of adenocarcinoma lung cancer (synchronous or metachrone)

        Exclusion Criteria:

        - adenocarcinoma previously treated by systemic oncologic treatment (chemotherapy, targeted
        therapy, immunotherapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cyrille Confavreux, MD, PhD</last_name>
    <phone>+33 4 72 11 74 79</phone>
    <email>cyrille.confavreux@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadège Trehet-Mendel</last_name>
    <phone>+33 4 72 11 74 46</phone>
    <email>centre.prevention@wanadoo.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Hôpital Edouard Herriot - Centre des Métastases Osseuses (CEMOS)</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyrille Confavreux, MD, PhD</last_name>
      <phone>+33 4 72 11 74 79</phone>
      <email>cyrille.confavreux@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nadège Trehet-Mendel</last_name>
      <phone>+33 4 72 11 74 46</phone>
      <email>centre.prevention@wanadoo.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <last_update_submitted>June 22, 2016</last_update_submitted>
  <last_update_submitted_qc>June 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>Bone metastases</keyword>
  <keyword>EGFR</keyword>
  <keyword>KRAS</keyword>
  <keyword>Bone biomarkers</keyword>
  <keyword>Metabolic parameters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

